Pharma Likelihood Of Approval
We are the trusted, gold standard intelligence provider to the world’s largest industries
GlobalData powers faster, more informed decisions with:
- Granular industry intelligence: We develop deep, vertical-specific intelligence tailored to your industry, providing 360° insight.​
- Exhaustive coverage: We synthesize our vast data universe into formats that support your decision-making needs, covering the sectors, themes, companies and geographies that matter to you. ​
- Proprietary datasets: We provide you with access to untapped pools of intelligence generated from our proprietary datasets and primary research capabilities. ​
- Robust methodologies: The quality and timeliness of our data is a key differentiator. We leverage robust research methodologies to turn millions of data points into trusted intelligence.
Thousands of companies, government organizations, and decision makers rely on GlobalData
We have a track record of serving truly diverse clients, including:
- Corporates: From helping the C-suite refine strategy to powering innovation in marketing and R&D, our corporate use cases are endless. ​
- Investment firms: We help financial analysts develop robust long-term strategies and get alpha signals before the rest. ​
- Professional services: We give consultants, legal, and accounting firms the critical insights to make faster, more informed decisions. ​
- Other sectors: From media to academia, we work with sectors as diverse as our data. ​
The trusted, actionable and future-proof insight you need to stay ahead
We have decades of experience in being the gold standard intelligence provider based on: ​
- Unique data: Proprietary datasets built from terabytes of data. Our unmatched intelligence gives you true strategic advantage.
- Expert analysis: Leverage collective expertise. Count on our extensive team of researchers, analysts, subject matter experts, and journalists, plus thousands of external thought-leaders.​
- Real intelligence over AI: Experience a level of analysis that leaves AI in the dust. Unlock the proprietary datasets unseen by AI and gain a decisive edge. ​
- Time-saving research solutions: Save hundreds of hours on research. Our comprehensive reports let you focus on delivering actionable insights - not searching for them. ​
- Unparalleled global coverage: Tap into insights from anywhere. Our extensive global coverage offers an unrivalled view of the market landscape.​
- One platform: Access all our unique data, expert analysis, and innovative solutions on one platform. ​
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model - Belantamab Mafodotin in Multiple Myeloma (Kahler Disease)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Belantamab Mafodotin in Multiple Myeloma (Kahler Disease) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Belantamab Mafodotin in Multiple Myeloma (Kahler Disease) Drug...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model - Loncastuximab Tesirine in Burkitt Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Loncastuximab Tesirine in Burkitt Lymphoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Loncastuximab Tesirine in Burkitt Lymphoma Drug Details: Loncastuximab Tesirine (Zynlonta) is...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model - Loncastuximab Tesirine in Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Loncastuximab Tesirine in Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Loncastuximab Tesirine in Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma) Drug...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model - KNX-100 in Opium (Opioid) Addiction
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - KNX-100 in Opium (Opioid) Addiction report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. KNX-100 in Opium (Opioid) Addiction Drug Details: KNX-100 is under...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model - S-65487 in Non-Hodgkin Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - S-65487 in Non-Hodgkin Lymphoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. S-65487 in Non-Hodgkin Lymphoma Drug Details: S-65487 is under development for...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model - Gene Therapy To Target CD22 For Oncology in Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Gene Therapy To Target CD22 For Oncology in Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data....
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model - ATI-2138 in Psoriasis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ATI-2138 in Psoriasis report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ATI-2138 in Psoriasis Drug Details: ATI-2138 is under development for the treatment...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model - Sepiapterin in Phenylketonuria (PKU)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Sepiapterin in Phenylketonuria (PKU) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Sepiapterin in Phenylketonuria (PKU) Drug Details: Sepiapterin (PTC-923 (CNSA-001)) is under...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model - ABP-671 in Gouty Arthritis (Gout)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ABP-671 in Gouty Arthritis (Gout) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ABP-671 in Gouty Arthritis (Gout) Drug Details: ABP-671 is under...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model - Loncastuximab Tesirine in B-Cell Non-Hodgkin Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Loncastuximab Tesirine in B-Cell Non-Hodgkin Lymphoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Loncastuximab Tesirine in B-Cell Non-Hodgkin Lymphoma Drug Details: Loncastuximab...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.